Drug Trial Radar · NCT07309055
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
201
Planned (sponsor's estimate)
Start
Mar 21, 2026
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
Conditions
- Adolescents With Moderate-to-severe Atopic Dermatitis
Interventions
SHR-1819 InjectionDrug
SHR-1819 injection.
SHR-1819 Injection PlaceboDrug
SHR-1819 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with Eczema Area and Severity (EASI)-75.Time frame: At week 16.
- Proportion of patients with an Investigator's Global Assessment (IGA) score of either 0 or 1.Time frame: At week 16.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.